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A New Way to Classify  
Genetic Skin Disease
Celia Moss1
Genetic disorders with skin manifestations often affect other organs as well, and 
diseases with a similar array of features might be linked pathogenetically. Classifying 
disorders by individual phenotypic components may reveal clusters with a common 
genetic cause and elucidate pathogenic links. If components are categorized inade-
quately, however, the method will simply confirm what is known, obscure true links, 
and suggest false ones.
Journal of Investigative Dermatology (2009) 129, 2543–2545. doi:10.1038/jid.2009.292
In this issue, Feramisco and colleagues 
identify 688 genetic skin disorders with 
both a characteristic cutaneous phe-
notype and a distinct molecular basis. 
The number of known genodermatoses 
has risen linearly since 1991, when 
about 90 such disorders were cataloged 
(Moss, 1991), through 2006, when we 
tabulated 580 such diseases (Leech and 
Moss, 2007). As the number of known 
genodermatoses increases, it becomes 
both more necessary and more rewarding 
to organize this information. Clinicians 
want catalogs they can search for a diag-
nosis; biologists need precise clinical 
descriptors to make sense of molecular 
information; and new patterns emerge 
as we arrange the mosaic fragments. 
Feramisco and colleagues present a sys-
tem of describing genodermatoses in 
terms of their individual cutaneous and 
systemic features in order to explore their 
relationships with one another and with 
genes and molecular pathways.
nosology of skin disease
Dermatologists have long sought to clas-
sify skin disorders. In the eighteenth and 
early nineteenth centuries, Joseph Plenck 
of Vienna, the Edinburgh physicians 
Robert Willan and Thomas Bateman, 
the Parisian Louis Marc Alibert, and the 
American Noah Worcester categorized 
dermatoses according to lesion type, 
inspired by the Linnaean system for 
plants (Connor, 2004). By the mid-nine-
teenth century, a better understanding 
of etiology facilitated pathological clas-
sification, led by Ferdinand Hebra of 
Vienna, and this is reflected in the chap-
ter headings of many standard dermatol-
ogy textbooks. Meanwhile, politicians 
and reformers were also taking an inter-
est in nosology; the first International List 
of Causes of Death, issued in 1900, was 
the forerunner of the 1989 International 
Classification of Diseases (ICD10), which 
is still in use (see “Web Resources”). 
Detailed though it is, the ICD10 does not 
meet the needs of dermatologists, and the 
British Association of Dermatologists has 
developed its own comprehensive diag-
nostic and procedural dictionaries with a 
clinically logical hierarchy of terms, more 
detailed than, but still mapped to, the 
ICD10 (see “Web Resources”).
Feramisco et al. (2009, this issue) use 
the classification and disease descrip-
tions of the geneticist Victor McKusick 
(1921–2008), who in 1966 published 
the first catalog of known genetic traits, 
Mendelian Inheritance in Man; 40 years 
later, he was still contributing to the online 
version, OMIM (see “Web Resources”). 
The distinctive tomes can still be seen 
on dermatologists’ bookshelves; for me, 
the silver ninth edition was a significant 
acquisition. McKusick’s classification is 
admirably simple: a broad split by mode 
of inheritance and, within that, alpha-
betical listings. The clinical features are 
described succinctly and authoritatively, 
together with genes and allelic variants. 
OMIM is part of the National Center for 
Biotechnology Information Entrez sys-
tem, which provides a massive informa-
tion base, linking, for example, clinical 
descriptions (OMIM) with genes, proteins, 
1Department of Dermatology, Birmingham Children’s Hospital, Birmingham, UK
Correspondence: Celia Moss, Department of Dermatology, Birmingham Children’s Hospital, Steelhouse 
Lane, Birmingham B4 6NH, UK. E-mail: celia.moss@bch.nhs.uk
commentary
2544 Journal of Investigative Dermatology (2009), Volume 129
and biosystems (pathways and systems of 
interacting molecules). Dr McKusick died 
in 2008.
Describing phenotypes
Feramisco et al. identified 826 OMIM dis-
ease entries with both skin manifestations 
and a defined genotype. They excluded 
138 with “undesignated” cutaneous 
pheno types, leaving 688 “disease units” 
(i.e., diseases with a distinct genotype), 
separately listing phenocopies represent-
ing genetic heterogeneity. For later analy-
sis they reduced the number to 560 by 
counting such phenocopies only once. 
They tabulated the 688 disease units 
alphabetically, with OMIM numbers, 
gene, and locus, in a manner similar to 
that of Leech and Moss (2007). They then 
broke down the phenotypes of these dis-
orders into 1,640 cutaneous and 2,551 
extracutaneous features using the clinical 
entries in OMIM—a reasonably straight-
forward, if laborious, process. The next 
stage was necessary but more subjective: 
reducing the number of parameters by 
merging features into groups. The cutane-
ous categories are in some cases anatomi-
cal (e.g., hair/nails), whereas in others 
they are morphological (e.g., blistering) 
or pathological (e.g., autoimmune), so 
the categories are not mutually exclu-
sive. Some skin categories are broad—
for example, “nails” includes everything 
from anonychia to pachyonychia and 
onychogryposis; some are narrow (e.g., 
“hypo/anhidrosis”). Systemic categories 
are mostly defined by organ and are nec-
essarily much broader. Cutaneous phe-
notypes were thus categorized into 18 
numbered groups with alphabetical sub-
groups and extracutaneous features into 
17 alphabetical groups (cleverly using the 
initial letter of the organ system) with num-
bered subgroups. So type 1 Waardenburg 
syndrome becomes 2C, 11C; A, D1, U, 
signifying hypopigmentation and change 
in hair and auditory, dysmorphism, 
and urogenital anomalies. Junctional 
epidermolysis bullosa with pyloric atre-
sia becomes 4B, 6,16,11D,17;G1,G2,U, 
signifying skin aplasia/fragility, blistering, 
mucosal and nail involvement and con-
genital malformation of the gut, other gut 
involvement, and urogenital anomaly. 
The catalog is named “CGenDerm” and 
is presented as an Excel spreadsheet.
The selection of categories was no 
doubt difficult, and the authors provide 
no information about how it was carried 
out. Some allocations are surprising. For 
example, teeth are considered systemic 
rather than cutaneous and are not includ-
ed in the description of hypohidrotic 
ectodermal dysplasia. The authors chose 
to divide the cornifying disorders into 1A 
xerosis, 1B hyperkeratosis not otherwise 
specified, 1C hyperkeratosis acanthosis 
type, and 1D hyperkeratosis ichthyosis/
scaling type. Where does that leave the 
palmoplantar keratodermas? 1B appar-
ently. Darier’s disease is also allocated 
to 1B and also, curiously, to 10 (immune 
mediated). It seems possible that the 
choice of category might have been 
informed consciously or unconsciously 
by a knowledge of genotype: the palmo-
plantar keratodermas are clinically 
distinct but genetically diverse, and trans-
membrane signaling may emerge as a 
theme among the 1B group.
Feramisco et al. (2009) refer to the 
process of categorizing individual disease 
features as “phenotype deconvolution.” 
A similar approach was used 25 years 
ago by Freire-Maia and Pinheiro (1984), 
who classified 117 ectodermal dysplasias 
according to whether they affected hair 
(1), teeth (2), nails (3), or sweat glands 
(4). To some extent, the same process 
has been used in clinical terms, such as 
odonto-tricho-ungual-digital-palmar and 
LEOPARD syndromes. Although this 
may be a rational alternative to nam-
ing diseases after a particular organ, 
feature, physician, or patient, clinicians 
generally prefer a simpler, if more lim-
ited, term. Although still widely cited, 
the 1-2-3-4 nomenclature never caught 
on among clinicians, and it is difficult to 
imagine the approach of Feramisco et al. 
doing so either. However, the “bottom-
up” approach of searching for diagnoses 
on individual clinical features is highly 
effective and widely used, for example, 
in Smith’s Recognizable Patterns of 
Human Malformation (Jones, 2006), 
the London Medical Databases (see 
“Web Resources”), and, indeed, OMIM. 
CGenDerm was designed to enable 
biologists to interpret clinical data, not to 
make life easier for clinicians (at least not 
directly), but it could easily be reformat-
ted to that end.
clustering by phenotype
The purpose of CGenDerm is to highlight 
relationships among disorders to guide 
research. First, the authors used cluster 
analysis based on the presence or absence 
of individual cutaneous and systemic fea-
tures. For example, diseases with café-
au-lait macules fall into a central nervous 
system tumor cluster (e.g., neuroblastoma 
and neurofibromatosis type 2), a chromo-
somal instability cluster (e.g., Bloom’s 
syndrome, Fanconi’s syndrome, and 
ataxia telangiectasia), and an NF1 cluster 
(neurofibromatosis type 1 and Watson’s 
syndrome). For laboratories interested in 
a particular gene or pathway, this might 
identify other candidate disorders, and 
it would be interesting to include geno-
dermatoses for which the pathogenesis 
is currently unknown. The ectodermal 
dysplasias might also be analyzed in 
this way, using the 1-2-3-4 classifica-
tion. The subjective allocation of features 
to categories and the degree of subclas-
sification might, however, prejudge the 
findings and produce “red herrings.” It is 
not surprising that a skin disease cluster 
featuring systemic malignancy (Bloom’s 
syndrome, Fanconi’s syndrome, and 
ataxia telangiectasia) exhibits a com-
mon pathogenetic feature (chromosom-
al instability). Conversely, the analysis 
unexpectedly clusters McCune–Albright 
and Rubinstein–Taybi syndromes on the 
basis that both have café-au-lait macules 
and auditory, skeletal, and ocular abnor-
malities; the disparate systemic features 
of the two disorders are masked by the 
broad systemic groupings, and the link 
might not be real. The same applies to 
Fanconi’s syndrome and LEOPARD syn-
drome, linked by sharing hyperpigmen-
tation, café-au-lait macules, deafness, 
abnormal growth, and neurological and 
musculoskeletal disorders, the last three 
of which are particularly broad groups. 
CGenDerm must be vindicated by eluci-
dating new pathogenetic links and testing 
prospectively with “orphan” diseases—
those whose genetic basis is unknown.
|Clustering by phenotype may help identify disorders and 




The authors examined 501 genes respon-
sible for the 560 genodermatoses defined 
by a unique OMIM entry. The mismatch is 
attributable to the possibility that a single 
gene can cause more than one disease 
(allelic variants and pleiotropy) and, con-
versely, a single disease can be caused 
by different genes (phenocopies and 
genetic heterogeneity). Genes operate 
within intricate pathways and networks, 
many of which are known. The authors 
use existing software to map these 501 
genes onto these known networks, high-
lighting nodes and groups of disorders. 
This exercise does not take into account 
variation caused by type of mutation, let 
alone epigenetic factors. Nonetheless, 
the authors demonstrate overlapping 
networks of genes—for example, those 
causing depigmentation, deafness, or 
both—and this process will undoubtedly 
reveal new candidate genes for disorders 
of unknown cause. This type of analysis 
could be applied to the 1-2-3-4 ecto-
dermal dysplasia classification now that 
several ectodermal dysplasia genes and 
pathways are known.
Where does this take us?
Despite some intrinsic limitations and 
simplifications, this analytical approach 
may help researchers identify candidate 
disorders and genes for future study. 
CGenDerm can be improved and extend-
ed in the future. It might be adapted to form 
a searchable database to aid clinicians. It 
remains to be seen whether the analyti-
cal methods will tell us more than existing 
search engines and Sherlockian deduc-
tion—a process that works only because 
the author already knows the answer.
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Stromal Collagenase in Melanoma:  
A Vascular Connection
Veli-Matti Kähäri1 and Risto Ala-aho1
In this issue, Zigrino et al. report on the role of host-derived mouse collagenase-3 
(matrix metalloproteinase (MMP)-13) in melanoma growth and metastasis using a 
mouse model that lacks MMP-13. The authors demonstrate that vascularization of 
cutaneous melanomas in these mice is impaired compared with that of controls. 
This study emphasizes the importance of stromal murine MMP-13, a functional 
homologue of human MMP-1, in tumor progression.
Journal of Investigative Dermatology (2009) 129, 2545–2547. doi:10.1038/jid.2009.298
Proteinases in tumor growth
Tumor progression is a multistage pro-
cess in which malignant cells invade 
surrounding tissue and metastasize to dis-
tant organs. An important stage of tumor 
invasion is the loss of an intact basement 
membrane. Subsequently, malignant 
cells metastasize to other organs by 
invading blood or lymphatic vessels. 
Tumor cells then enter blood or lymph 
circulation, attach at a distant location, 
and degrade the basement membranes 
and extracellular matrix (ECM) at the 
sites of metastases. Furthermore, angio-
genesis is required for tumor growth, and 
tumor-induced lymphangiogenesis plays 
an important role in tumor metastasis 
(Karpanen and Alitalo, 2008).
collagenases
Collagenase-1 (matrix metalloproteinase 
(MMP)-1), collagenase-2 (MMP-8), and 
collagenase-3 (MMP-13) are principal 
secreted proteinases capable of cleaving 
native fibrillar collagens of types I, II, III, 
V, and IX. In addition to MMP-1, MMP-8, 
and MMP-13, gelatinase-A (MMP-2) has 
a weak catalytic activity toward fibrillar 
collagens (Ala-aho and Kähäri, 2005). 
Furthermore, membrane-type-1 MMP 
(MMP-14) cleaves fibrillar collagens. 
Collagenases vary in their ability to cata-
lyze fibrillar collagens.
The first MMP to be identified, a col-
lagenase, was purified from the tails of 
tadpoles by Gross and Lapière (1962). 
The first human MMP to be identified, 
MMP-1, was cloned from adult skin fibro-
blasts (Goldberg et al., 1986). Human 
MMP-1 is expressed in physio logical pro-
cesses, for example, during embryonic 
development and wound healing, as well 
as under a number of pathological condi-
tions, including chronic cutaneous ulcers 
and various malignant tumors. MMP-1 
is expressed by a variety of normal cells 
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